Tag
Long-term intensive BP control led by trained nonphysician community providers significantly lowers cardiovascular risk over 7 years, with benefits persisting 3 years post-intervention in rural China.
This review synthesizes evidence on physician-focused financial incentives for hypertension control, highlighting nuanced impacts on clinical decisions, documented blood pressure control, and cardiovascular outcomes, with a focus on both ov
The PINGS trial demonstrates that a 12-month nurse-led mobile health intervention significantly improves blood pressure control among Ghanaian stroke survivors, with 67% achieving target BP versus 43% in usual care. This pragmatic approach
The TOUCHED randomized trial found that an ED-initiated education plus mHealth and pharmacist/APRN consultation reduced systolic blood pressure by 4.9 mm Hg at 6 months versus usual care in patients discharged with elevated BP.
Mediation analysis of INTERACT3 reveals that systolic blood pressure and blood glucose control are primary drivers of functional recovery benefits in acute intracerebral hemorrhage care bundles.
This multicenter randomized trial in India shows that three dual antihypertensive combinations—amlodipine-perindopril, perindopril-indapamide, and amlodipine-indapamide—are equally effective and well-tolerated for 24-hour blood pressure con
A recent randomized clinical trial demonstrates amiloride’s noninferiority to spironolactone in lowering systolic blood pressure in resistant hypertension, offering a promising alternative therapy.
Baxdrostat, a novel aldosterone synthase inhibitor, significantly reduces systolic blood pressure in patients with uncontrolled or resistant hypertension, offering a new therapeutic option with a favorable safety profile.
Intensive blood pressure control reduces cardiovascular events across all risk levels, with greater absolute benefits in higher-risk patients despite increased adverse events, supporting tailored treatment based on cardiovascular risk.
